Welcome to our dedicated page for Marpai SEC filings (Ticker: MRAI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Marpai, Inc. (MRAI) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Marpai’s filings describe its business as a technology platform company operating subsidiaries that provide Third-Party Administration (TPA), Pharmacy Benefit Management (PBM) and value-oriented health plan services to employers that directly pay for employee health benefits. Its Class A common stock is listed on the OTCQX Market under the symbol MRAI.
Through periodic and current reports, Marpai presents financial statements, details of its operating performance and information about its capital structure. For example, Form 8-K filings included in this record describe private placements of Class A common stock and warrants under Securities Purchase Agreements, with proceeds intended for working capital and general corporate purposes. Other 8-K filings reference amendments to the company’s certificate of incorporation, such as the authorization of blank-check preferred stock, and the release of selected financial information for specific reporting periods.
Annual proxy materials, such as the definitive proxy statement (DEF 14A), outline governance matters, including the election of directors, ratification of the independent registered public accounting firm and proposals to amend the certificate of incorporation. These documents also confirm key facts such as Marpai’s Delaware incorporation, its Tampa, Florida office location and the voting rights associated with its Class A common stock.
On this page, users can review Marpai’s Forms 10-K and 10-Q (when available), current reports on Form 8-K, proxy statements and other filings. Stock Titan’s tools can surface summaries and key points from longer documents, helping readers understand topics such as equity issuances, changes to the capital structure, governance proposals and how Marpai presents its TPA and PBM operations in official filings.
Marpai, Inc. entered into a related-party financing arrangement by issuing a promissory note for
Marpai, Inc. reported that President Dallas Scrip resigned from his position, effective January 30, 2026. The company stated that his resignation was not due to any disagreement regarding operations, policies, or practices.
As a result, the Board appointed current Chief Executive Officer Damien Lamendola, age 70, to also serve as President effective the same date, consolidating both roles under one executive. He has been CEO since November 2023 and has served on the Board since April 2021.
The filing notes Mr. Lamendola’s prior and ongoing leadership roles at various affiliated entities and references several securities purchase agreements between Marpai, entities controlled by him, and an immediate family member, with the material terms previously disclosed and incorporated by reference. Aside from those transactions and his existing compensation, the company states there are no additional related-party transactions reportable under Item 404(a) or arrangements leading to his appointment.
Marpai, Inc. received a Schedule 13G/A filing from Intelligent Fanatics Capital Management LLC, IFCM MicroCap Fund LP, and Ian Cassel reporting a significant ownership stake. The filing states that IFCM MicroCap Fund LP beneficially owns 1,325,636 common shares, representing 5.6% of Marpai’s common stock. Intelligent Fanatics Capital Management LLC, as general partner of the fund, and Ian Cassel, as the sole managing member of IFCM, each report shared voting and shared dispositive power over these 1,325,636 shares and no sole voting or dispositive power.
The filing explains that the securities are held directly by IFCM MicroCap Fund LP and that Mr. Cassel may be deemed a beneficial owner through his interests in the fund, while he disclaims beneficial ownership beyond his economic interest. The reporting persons certify that the shares were not acquired and are not held for the purpose of changing or influencing control of Marpai.
Marpai, Inc. disclosed that it entered into a Securities Purchase Agreement with certain investors to raise approximately $350,000 in a private placement. The Company agreed to issue and sell 350,000 shares of Class A common stock together with warrants to purchase up to 700,000 additional shares of common stock, at a combined purchase price of $1.00 per share and accompanying warrant.
The common warrants have an exercise price of $1.00 per share, are exercisable immediately after closing, and remain exercisable for three years from issuance, with customary anti-dilution provisions. Marpai plans to use the proceeds for working capital and general corporate purposes, and granted investors a six‑month right to include the shares and warrant shares in any other registration of securities it files, subject to limited exceptions.
Marpai, Inc. reported Q3 results and flagged substantial doubt about its ability to continue as a going concern. Revenue was $4.037 million, down 42% year over year, as customer turnover reduced volumes. The quarter’s net loss was $3.494 million, with interest expense of $797 thousand reflecting higher-cost debt.
At September 30, 2025, cash and cash equivalents were $445 thousand against total liabilities of $46.099 million and a stockholders’ deficit of $33.346 million. Working capital was negative $10.7 million. Convertible debentures had a net carrying amount of $9.840 million bearing 14% interest with $250 thousand monthly principal payments; liabilities due to AXA totaled $18.952 million due by December 31, 2028.
Year to date, revenue was $14.111 million (down 34.6%) and operating loss improved to $8.627 million due to cost reductions across G&A, facilities, and depreciation. Management is exploring strategic alternatives and raised capital through several private placements. The company disclosed ongoing litigation relating to a lease subtenant dispute.
Marpai, Inc. (MRAI) filed a current report announcing it issued a press release with selected financial information for the three and nine months ended September 30, 2025. The release is provided as Exhibit 99.1.
The filing identifies the company’s Class A common stock trading on the OTCQX Market under the symbol MRAI. No additional operational or financial details are included in this report beyond the exhibit reference.
Marpai, Inc. (MRAI) director purchase disclosed. A director reported buying 100,000 shares of Class A common stock at $1.00 per share in a private placement on November 7, 2025, and received common warrants to purchase up to 200,000 additional shares at an exercise price of $1.00.
The warrants are exercisable immediately and remain exercisable until November 6, 2028. Following the transaction, the director directly owns 1,089,073 shares.
Marpai (MRAI) reported an insider transaction by a director. On 11/07/2025, the reporting person purchased 50,000 shares of Class A common stock at $1.00 per share and acquired common warrants for up to 100,000 shares with a $1.00 exercise price. The warrants are exercisable immediately and expire on 11/06/2028. Following the transaction, the insider beneficially owned 272,000 shares, held directly.
Marpai, Inc. (MRAI) insider transaction: Chief Operating Officer Dallas Scrip reported a private placement purchase on 11/07/2025 of 100,000 shares of Class A common stock at $1.00 per share and common warrants to purchase up to 200,000 additional shares. The warrants are exercisable immediately at $1.00 per share and remain exercisable for three years from the 11/07/2025 issuance date, expiring on 11/06/2028.
The securities are held indirectly by the Dallas S. Scrip and Michelle R. Script Trust, for which the reporting person and spouse serve as co‑trustees with shared voting and investment control.
Marpai, Inc. (MRAI) reported an insider purchase by director Robert Pons. On November 7, 2025, he bought 50,000 shares of Class A common stock in a private placement at $1.00 per share, together with common warrants to purchase up to 100,000 shares at an exercise price of $1.00.
The warrants are exercisable immediately and expire on November 6, 2028. Following the transaction, Pons beneficially owned 359,200 shares directly.